Viridian Therapeutics announced the completion of enrollment in its phase 3 clinical trials, THRIVE and THRIVE-2, targeting patients with thyroid eye disease (TED).
THRIVE-2, focused on chronic TED, surpassed its target of 159 patients, enrolling 188 participants—approximately 40% of these patients enrolled from US sites. Topline data for THRIVE-2 is expected by the end of 2024.
THRIVE, targeting active TED, had completed and exceeded its enrollment target in March 2024. Approximately 50% of the enrolled patients came from the US. Topline data for THRIVE is anticipated in September 2024.
Viridian’s lead candidate, VRDN-001, is an intravenous monoclonal antibody that acts as an IGF-1R inhibitor. VRDN-001 has shown promise in improving TED symptoms in phase 2 trials.
THRIVE, and THRIVE-2 trials compare VRDN-001 to a placebo, with a dosing regimen featuring a shorter infusion time and fewer infusions than existing treatments.
Viridian plans to initiate two subcutaneous VRDN-003 phase 3 clinical trials, REVEAL-1 and REVEAL-2, in August.
The successful enrollment in the VRDN-001 trials is a testament to the patient demand for treatment options in TED. Viridian is optimistic about the potential of VRDN-001 to address the unmet needs of patients with this debilitating condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
